Full text is available at the source.
DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus
DR10601, a new long-lasting treatment activating both appetite and blood sugar control systems for obesity and type 2 diabetes
AI simplified
Abstract
The plasma half-life of DR10601 following subcutaneous administration was 51.9 ± 12.2 hours.
- DR10601 shows dual activity on GLP-1 and glucagon receptors.
- A single dose of DR10601 (30 nmol/kg) achieved similar glycemic control and longer action duration compared to dulaglutide (10 nmol/kg).
- Administered once every 4 days at 90 nmol/kg, DR10601 produced effects on food intake and body weight that were nearly equivalent to daily liraglutide (40 nmol/kg) at 24 days.
- Repeated administration of DR10601 may lead to significant body weight loss in high-fat diet-induced obesity models.
AI simplified